8-K 1 y42372e8-k.txt OSI PHARMACEUTICALS, INC. 1 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 November 9, 2000 ---------------- Date of Report (Date of earliest event reported) OSI PHARMACEUTICALS, INC. ------------------------- (Exact name of registrant as specified in its charter) DELAWARE 0-15190 13-3159796 -------------- ------------ ------------ (State or other jurisdiction of (Commission (I.R.S. Employer incorporation) File Number) Identification No.) 106 CHARLES LINDBERGH BOULEVARD UNIONDALE, NY 11553 ---------------------------------- (Address of principal executive offices) (516) 222-0023 ---------------------------- (Registrant's telephone number, including area code) 2 ITEM 5. OTHER EVENTS On November 9, 2000 OSI Pharmaceuticals, Inc., a Delaware corporation (the "Company") announced updated findings from two ongoing clinical studies of the Company's lead anti-cancer drug candidate, OSI-774, as a single agent. The data was communicated by investigators at the European Organization for the Research and Treatment of Cancer symposium on new drugs in cancer therapy in Amsterdam. Detailed information regarding the findings were released by the Company in a press release on November 9, 2000 attached as an exhibit hereto and incorporated by reference herein. ITEM 7. EXHIBITS -------------------------------------------------------------------------------- EXHIBIT NO. DESCRIPTION -------------------------------------------------------------------------------- 99 Press release, dated November 9, 2000 -------------------------------------------------------------------------------- 3 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 9, 2000 OSI PHARMACEUTICALS, INC. By: /s/ Robert L. Van Nostrand ----------------------------------------- Name: Robert L. Van Nostrand Title: Vice President and Chief Financial Officer, Secretary and Treasurer 4 EXHIBIT INDEX -------------------------------------------------------------------------------- EXHIBIT NO. DESCRIPTION -------------------------------------------------------------------------------- 99 Press release, dated November 9, 2000. --------------------------------------------------------------------------------